Genetic Technologies Limited

ASX:GTG ISIN:AU000000GTG7

Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance. 
 
     

View in Other Languages

News

Australian Market Report of January 7: Optimism over Iron Ore Prices

🕔1/7/2010 9:30:30 AM 13294

Australian stocks ended flat on Wednesday as shares gave up early gains in the afternoon dragged by banks. Miners advanced as investors were optimistic about the iron ore prices. At the close, the benchmark S&P/ASX200 index was up 1.6 points at 4925.9 points, while the broader All Ordinaries index lifted 7.7 points, or 0.15 per cent, to 4947.2 points.

Read Full Article

Genetic Technologies (ASX: GTG) Advise on Progress with Intellectual Property Licensing on Non-coding DNA

🕔1/15/2008 1:19:11 PM 6126

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) wishes to advise of its progress in licensing its core intellectual property pertaining to non-coding DNA.

Read Full Article

Genetic Technologies Limited ASX: GTG - Company Update - Mr Michael Ohanesian, CEO

🕔10/17/2007 2:00:00 PM 5885

Genetic Technologies Limited (ASX: GTG) - Company Update - Mr Michael Ohanesian, CEO; Genetic Technologies Limited (ASX: GTG) present the following audio webcast regarding "Company Update". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

Aegis Equities Research Announce Health and Life Science Review, August 2006

🕔8/15/2006 2:42:55 PM 14077

The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.

Read Full Article

Genetic Technologies Expands Paternity Testing Services into China

🕔6/16/2006 4:21:29 PM 6428

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that it has entered into an agreement with DNA Bioservices Pty. Ltd. to provide paternity testing services to China.

Read Full Article

GENETIC TECHNOLOGIES LIMITED Deciphering the Lingo - Biotechs Forum; ASX: GTG - Dr Mervyn Jacobson, CEO

🕔4/24/2006 3:15:00 PM 6941

GENETIC TECHNOLOGIES LIMITED Deciphering the Lingo - Biotechs Forum; (ASX: GTG) - Dr Mervyn Jacobson, CEO; Boardroomradio is pleased to announce that GENETIC TECHNOLOGIES LIMITED (ASX: GTG) has publis

Read Full Article
###

46,917 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 29) (Last 30 Days: 62) (Since Published: 8616) 

Company Data

    Fax
  • (03) 9417 2987 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 1987/07/30 
  • Homepage
  • www.gtg.com.au/

More News Results

  • 2024/06/28: Resignation of CFO and Company Secretary*
  • 2024/06/28: Business Update - June 2024*
  • 2024/06/25: GeneType identifies 79.5% at risk of serious disease*
  • 2024/06/24: Change in substantial holding*
  • 2024/06/21: GTG Live Investor Webinar and Q&A - June 27*
  • 2024/06/18: GTG Expands Operational Capacity in North America*
  • 2024/06/12: Notification regarding unquoted securities - GTG*
  • 2024/06/05: GeneType and Stayhealthy Announce Landmark Distribution Agre*
  • 2024/06/05: Change in substantial holding*
  • 2024/05/29: Launch of test for 100% risk of breast and ovarian cancer*
*refer to company website